ArticlePDF Available

Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet


Abstract and Figures

The aim of this study was to comparatively evaluate the long-term effects of psyllium husk and guar gum supplementation on metabolic syndrome (MS) components. We randomised 141 MS patients to soluble psyllium husk powder or guar gum 3.5 g t.i.d. to be taken 20 min before the main 2 meals, or to a standard diet for a cumulative period of 6 months. Both fibres significantly improved body mass index (−7.2% vs. −6.5%), fasting plasma glucose (−27.9% vs. −11.1%) and insulin (−20.4% vs. −10.8%), HOMA Index (−39.2% vs. −16.7%), glycated haemoglobin (−10.4% vs. −10.3%), low-density lipoprotein cholesterol (−7.9% vs. −8.5%) and apolipoprotein B (−10.5% vs. −5.6%), after 6 months of treatment. Only the psyllium supplementation exerted a significant improvement on plasma triglyceride concentration (−13.3%) and systolic (−3.9%) and diastolic blood pressure (−2.6%). No significant difference was observed regarding the standard diet group in comparison to the baseline. On the basis of our data, psyllium could be more strongly indicated for patients that have to reduce a large number of cardiovascular risk factors, while guar gum could be more rapidly efficacious in strengthening the effect of diets aimed at reducing body weight. KeywordsMetabolic syndrome-Soluble fibres-Hypertension-Hypercholesterolaemia-Hypertriglyceridaemia-Hyperglycaemia-Cardiovascular risk
Content may be subject to copyright.
Mediterr J Nutr Metab (2010) 3:47–54
DOI 10.1007/s12349-009-0056-1
Psyllium improves dyslipidaemia, hyperglycaemia and hyperten-
sion, while guar gum reduces body weight more rapidly in patients
affected by metabolic syndrome following an AHA Step 2 diet
Arrigo F.G. Cicero · Giuseppe Derosa · Marilisa Bove ·
Fabrizio Imola · Claudio Borghi · Antonio V. Gaddi
Received: 9 April 2009 / Accepted: 9 June 2009 / Published online: 21 October 2009
© Springer-Verlag 2009
A.F.G. Cicero ()
Atherosclerosis and Metabolic Diseases Research Unit
Internal Medicine, Aging and Kidney Diseases Department
S. Orsola-Malpighi Hospital, University of Bologna
Poliambulatorio Pad. 2
Via Albertoni 15, 40138 Bologna, Italy
G. Derosa
Department of Internal Medicine and Therapeutics
University of Pavia
Pavia, Italy
M. Bove · F. Imola · C. Borghi · A.V. Gaddi
“GC Descovich” Atherosclerosis Research Centre
“D. Campanacci” Clinical Medicine and
Applied Biotechnology Department
University of Bologna
S. Orsola-Malpighi Hospital
Via Massarenti 9, 40138 Bologna, Italy
nificant improvement on plasma triglyceride concentra-
tion (–13.3%) and systolic (–3.9%) and diastolic blood
pressure (–2.6%). No significant difference was observed
regarding the standard diet group in comparison to the
baseline. On the basis of our data, psyllium could be
more strongly indicated for patients that have to reduce a
large number of cardiovascular risk factors, while guar
gum could be more rapidly efficacious in strengthening
the effect of diets aimed at reducing body weight.
Keywords Metabolic syndrome · Soluble fibres · Hyper -
tension · Hypercholesterolaemia· Hypertriglyceridaemia
· Hyperglycaemia · Cardiovascular risk
It is well known that a dietetic approach is always beneficial
in the management of cardiovascular disease risk in people
affected by relevant metabolic diseases such as hypercholes-
terolaemia and diabetes, but also at a population level [1].
Increasing dietary fibre has been recommended as a
safe and practical approach for cholesterol reduction [2].
However, “dietary fibre” is a collective term for a variety
of plant substances that are resistant to digestion by
human gastrointestinal enzymes [3]. Dietary fibres can
be classified into two major groups depending on their
solubility in water. The structural or matrix fibres (lignin,
cellulose and some hemicelluloses) are insoluble, where-
as the natural gel-forming fibres (pectin, gums,
mucilages, and the remainder of the hemicelluloses) are
soluble. Studies have focused on soluble fibres such as
oats, psyllium, pectin and guar gum, and qualitative
reviews have suggested that these fibres lower total and
low-density lipoprotein (LDL) cholesterol [4, 5]. Water-
Abstract The aim of this study was to comparatively
evaluate the long-term effects of psyllium husk and guar
gum supplementation on metabolic syndrome (MS) com-
ponents. We randomised 141 MS patients to soluble psyl-
lium husk powder or guar gum 3.5 g t.i.d. to be taken 20
min before the main 2 meals, or to a standard diet for a
cumulative period of 6 months. Both fibres significantly
improved body mass index (–7.2% vs. –6.5%), fasting
plasma glucose (–27.9% vs. –11.1%) and insulin (–20.4%
vs. –10.8%), HOMA Index (–39.2% vs. –16.7%), glycat-
ed haemoglobin (–10.4% vs. –10.3%), low-density
lipoprotein cholesterol (–7.9% vs. –8.5%) and apolipo -
protein B (–10.5% vs. –5.6%), after 6 months of treat-
ment. Only the psyllium supplementation exerted a sig-
insoluble wheat fibre and cellulose have no significant
effect unless they displace foods supplying saturated fats
and cholesterol [6]. Among soluble fibres, psyllium
appears to be the one with the highest antihypercholes-
terolaemic efficacy [7]. Beyond the antihypercholestero-
laemic effect, psyllium appears to also have other posi-
tive effects that could be beneficial for the management
of patients at high cardiovascular risk, such as those
affected by metabolic syndrome (MS). In fact, it showed
a slight antihypertensive effect [8], an antihypergly-
caemic action [9, 10] and a slowing effect on gastric
emptying that is supposed (but not yet demonstrated) to
be beneficial in weight loss dietary regimens [11, 12].
Guar gum appears to have a positive metabolic effect
on cholesterolaemia and insulinaemia [13], and a slowing
effect on gastric emptying [14] as well.
Despite all this intriguing evidence, to the best of our
knowledge, until now no study has considered the effect
of a dietary psyllium supplement on these parameters in
patients affected by MS or directly compared it to any
other kind of fibre in the management of this condition.
For this reason, the aim of our study was to compara-
tively evaluate the long-term effect of a dietary supple-
mentation of psyllium husk and guar gum on a large
range of parameters of MS patients.
Patients and methods
One hundred and forty-one age-matched non-smoking
Caucasian patients not taking antihypercholesterolaemic
or antidiabetic treatment, or under stabilised antihyperc-
holesterolaemic and antidiabetic treatment for at least 6
months, who complied with at least three of the follow-
ing criteria were consecutively recruited for the study at
the Atherosclerosis and Metabolic Disease Ambulatory
of the University of Bologna and the Diabetes Center of
the University of Pavia:
- waist circumference: men >40 in (102 cm); women
>35 in (88 cm);
- plasma triacylglycerol (TG) 1.70 mmol/l;
- plasma high-density lipoprotein cholesterol (HDL-
C): men <1.03 mmol/l; women <1.29 mmol/l;
- blood pressure 130/ 85 mmHg or stabilised antihy-
pertensive treatment for at least 6 months
- fasting plasma glucose (FPG) 6.1 mmol/l.
These are the same criteria suggested by the third report
of the Adult Treatment Panel of the National Cholesterol
Educational Program for the diagnosis of MS [15].
Exclusion criteria included:
- severe hyperlipoproteinaemias;
- uncontrolled diabetes;
- active treatments with anticoagulant, anticancer and
antiretroviral drugs; and
- previous cardiovascular disease events.
The study was approved by the University of Pavia
ethical committee and all participants gave their written
The main baseline demographic, anthropometric and
laboratory characteristics of the subjects are reported in
Table 1.
Study design
During the first month, all patients received dietary advice
(according to Step 2 of the recommendations issued by the
American Heart Association (AHA)) [16] and any nutri-
tional supplement use was eliminated. Then, patients were
randomised to soluble psyllium husk powder (n= 46) or
partially hydrolysed guar gum (n= 46) 3.5 g b.i.d. to be
taken 20 min before the main two meals for 6 months.
These kinds of formulation represent the most widely mar-
keted soluble fibres in Italy. Another group was ran-
domised to continue the AHA Step 2 diet (n= 45).
At baseline, eligible patients received a box contain-
ing a 60-day supply of study medication and were
instructed to start with the first dose of the new medica-
tion on the day after their inclusion in the study. A sec-
ond box containing the study medication was given to
participants at the time of the scheduled control at the 2-
month visit and so on till the end of the study. At each
study visit, patients had to take back the envelopes of
each dose assumed in order to allow us estimate their
compliance to the treatment. They also had to note on a
specific form when and why they eventually did not take
a dose of the product. All medications were provided free
of charge.
The randomisation code was generated by the study
statistician who was the only person allowed to manage the
randomisation list. The randomisation code was broken
only after database lock, but could have been broken for
individual patients in cases of emergency. The randomisa-
tion was made up opening a previously prepared letter con-
taining the randomisation code that assigned the treatment.
A double-blind randomisation was made impossible
because the two fibres have a different colour and flavour.
At each visit, a registered dietician also monitored the
patient’s weight and dietary pattern, through the “Seven-
day questionnaire”, in order to evaluate compliance to
the AHA Step 2 diet [17].
Cuff trough systolic blood pressure (SBP) and diastolic
blood pressure (DBP) was measured using a standard mer-
cury sphygmomanometer (Korotkoff I and V) and a cuff of
48 Mediterr J Nutr Metab (2010) 3:47–54
appropriate size on the right arm with the patient sitting.
Measurements were always taken by the same investigator
in the morning before daily drug intake and after the sub-
ject had been resting for 10 min in a quiet room. The aver-
age of three successive blood pressure readings obtained at
1-min intervals was recorded. Heart rate was monitored at
each clinical visit and was measured after the patient had
been seated for at least 10 min.
Adverse events, intercurrent diseases and compli-
ance were checked at 4-week intervals during the active
treatment phase. Safety monitoring included physical
examination, vital sign assessment, weight and height
measurement, questioning about adverse events and
laboratory tests.
All study procedures followed were in accordance
with the Helsinki Declaration of 1975 as revised in 1983.
Laboratory measurements
The patients entered the research unit between 08:00 and
09:00, after a 12-h overnight fast. All collected samples
were transported within 4 h to a central laboratory at the
authors’ hospital.
A total of 15 ml of blood was collected. Plasma was
obtained by centrifugation at 1000 gfor 25 min at 4°C
and was tested for total cholesterol (TC) and TG concen-
trations using standardised enzymatic methods (TC,
CHOD-PAP; TG, TG without free glycerol; HITACHI
737; Hitachi, Tokyo, Japan). Determination of HDL-C
was performed after the precipitation of 1006 g/ml bot-
tom infranatant with dextran sulphate–magnesium chlo-
ride [18]. LDL-C was estimated by Friedewald’s formula
(LDL-C = TC–HDL-C–TG/5). The interassay coeffi-
cients of variation were 2.7% for TC, 9.1% for HDL-C
and 2.0% for TG. ApoAI and Apo B were measured
using immunoturbidimetric assays (Boehringer-
Mannheim, Mannheim, Germany); the inter- and intraas-
say CsV were 3% to 5%, respectively [19]. Lipoprotein
(a) was measured by a sandwich enzyme-linked
immunosorbent assay (ELISA) method, insensitive to the
presence of plasminogen, using the commercial kit
Macra-Lp(a) (SDI, Newark, DE, USA) [20]; the intra-
and interassay CsV of this method were 5% and 9%,
Plasma glucose was tested by the hexokinase/glu -
cose-6-phosphate dehydrogenase method using a
COBAS Mira Plus autoanalyser (Hoffmann–La Roche,
Basel, Switzerland) [21]. The interassay coefficient of
variation for glucose was 3.0%. Insulin was determined
using Phadiaseph Insulin radioimmunoassay (Pharmacia,
Uppsala, Sweden) [22]. HbA1c was measured by
Mediterr J Nutr Metab (2010) 3:47–54
Table 1 Characteristics of the subjects affected by the MS after the first month of AHA Step 2 diet and before randomisation
Psyllium group Guar group Step 2 AHA diet group
Number of subjects 48 (M/F = 1) 48 (M/F = 1) 45 (M/F = 0.9)
Age 58.4 ± 2.5 57.9 ± 1.8 57.2 ± 2.1
Body weight 80.2 ± 4.1 79.9 ± 4.5 80.1 ± 4.3
Body Mass Index 28.8 ± 1.5 28.6 ± 1.3 28.5 ± 1.6
Waist circumference (cm) 100.4 ± 10.3 101.7 ± 9.5 102.0 ± 8.3
Glycated haemoglobin (%) 6.7 ± 0.6 6.8 ± 0.7 6.6 ± 0.9
Fasting plasma glucose (mmol/l) 6.1 ± 1.2 6.0 ± 1.3 6.1 ± 1.3
Fasting plasma insulin (μU/ml) 25.2 ± 5.1 24.9 ± 5.8 25.0 ± 5.5
HOMA Index 7.4 ± 2.9 7.2 ±2.5 7.2 ± 2.8
Total cholesterol (mmol/l) 4.83 ± 0.6 4.94 ± 0.6 4.8 ± 0.7
LDL-cholesterol (mmol/l) 2.9 ± 0.3 3.0 ± 0.4 3.0 ± 0.3
HDL-cholesterol (mmol/l) 1.1 ± 0.13 1.2 ± 0.1 1.1 ± 0.1
Triacylglycerols (mmol/l) 1.8 ± 0.3 1.7 ± 0.2 1.7 ± 0.3
Apolipoprotein AI (mg/dl) 130 ± 18 129 ± 16 129 ± 14
Apolipoprotein B (mg/dl) 105 ± 22 107 ± 25 106 ± 20
Lipoprotein (a) (mg/dl) 17.1 ± 7.7 15.9 ± 6.4 17.0 ± 7.9
Homocysteine (μmol/l) 9.8 ± 3.1 9.6 ± 2.8 9.8 ± 2.9
Fibrinogen (mg/dl) 379 ± 42 384 ± 46 380 ± 48
Systolic blood pressure (mmHg) 131.4 ± 4.2 131.6 ± 4.0 131.0 ± 3.7
Diastolic blood pressure (mmHg) 84.6 ± 4.4 85.2 ± 3.6 84.5 ± 3.9
Daily energy intake (MJ) 4.9 ± 0.5 5.1 ± 0.4 5.0 ± 0.5
Carbohydrate (% of energy) 46.8 ± 1.7 46.2 ± 1.9 46.4 ± 1.9
Protein (% of energy) 20.2 ± 1.4 20.9 ± 1.7 21.0 ± 1.6
Total fat (% of energy) 33.0 ± 1.8 32.9 ± 1.5 32.6 ± 1.5
Saturated fat (% of fat) 29.1 ± 1.3 28.7 ± 1.6 28.5 ± 1.8
Polyunsaturated/saturated fats 0.6 ± 0.07 0.6 ± 0.09 0.6 ± 0.09
Cholesterol (mg) 265.4 ± 36.4 261.4 ± 30.1 263.8 ± 26.9
Total fibre (g) 14.6 ± 2.5 15.4 ± 1.9 14.8 ± 2.0
Soluble fibre (g) 3.9 ± 0.4 4.1 ± 0.8 3.8 ± 0.8
aminophenylboronic acid affinity chromatography (DIA-
MAT, Bio-Rad, USA; normal values 4.2–6.2%), with
intra- and interassay coefficients of variation of <2%
[23]. The estimate of insulin resistance was calculated by
homeostasis model assessment index (HOMA-IR) using
the formula:
HOMA-IR = FPI (μU/ml)FPG (mmol/l)/22.5
as described by Matthews et al. [24].
Fibrinogen was measured in tripotassium
EDTA–plasma with a standardised immunonephelomet-
ric method (BNA Behring). The CV was 3.3%.
Homocysteine was measured by a modified procedure
of Araki and Sako [25] with high-pressure liquid chro-
matography and fluorescence detection. The intra-assay
variation of the method was 2.5%.
An intention-to-treat analysis was conducted in patients
who had received at least one dose of study medication
and had a subsequent efficacy observation. Patients were
included in the safety analysis if they had received one
dose of trial medication after randomisation and had a
subsequent safety observation. The null hypothesis that
the change in mean studied parameters from baseline to
the end of 6 months of treatment did not differ signifi-
cantly among psyllium, guar and dietary treatments was
tested using analysis of variance (ANOVA) and analysis
of covariance (ANCOVA) models. The statistical signifi-
cance of the independent effects of treatment on the other
parameters was determined by ANCOVA. A one-sample
t-test was used to compare values obtained before and
after treatment administration, and two-sample t-tests
were used for between-group comparison. Then we car-
ried out a multivariate analysis to evaluate if the observed
changes in some variables (especially the insulin-resist-
ance related ones) is simply related to the body weight
change or to a specific dietary intervention. Statistical
analysis of data was performed by means of the SPSS
statistical software package for Window (version 11.0;
Chicago, IL); data are presented as mean ± SD. For all
statistical analysis, a pvalue less than 0.01 was consid-
ered statistically significant [26].
For the duration of the study, no significant change in
dietary habit or physical activity was observed. Adherence
to the AHA Step 2 diet was considered similar for all
groups, especially regarding energy consumption. The
main results of the study are summarised in Tables 2–4.
Metabolic effects
Long-term treatment of both tested fibres is associated
with a significant improvement in both glycaemic and
plasma lipid control in the studied subjects. After 4 and
6 months of psyllium supplementation, from baseline
values we observed a mean decrease in FPG of 1 mmol/l
(t = 3.01, p < 0.001) and 1.33 mmol/l (t = 6.59, p <
0.001), in FPI of 3.1 μU/ml (t = 2.81, p = 0.005) and 5.1
μU/ml (t = 4.90, p < 0.001), in HOMA Index of 2.1 (t =
4.47, p < 0.001) and 2.9 (t = 6.55, p < 0.001), in HbA1c
of 0.4% (t = 3.01, p < 0.001) and 0.7% (t = 5.71, p <
0.001), in TC of 0.18 mmol/l (n.s.) and 0.31 mmol/l (t =
2.72, p = 0.008), in LDL-C of 0.13 mmol/l (t = 3.92, p <
0.001) and 0.23 mmol/l (t = 5.69, p < 0.001), in Apo B
of 5 mg/dl (n.s.) and 11 mg/dl (t = 2.68, p = 0.009) and
in TG of 0.13 mmol/l (n.s.) and 0.24 mmol/l (t = 5.35, p
< 0.001).
After 4 and 6 months of guar supplementation, we
observed a mean decrease in FPG of 0.55 mmol/l (t = 2.69,
p = 0.009) and 0.66 mmol/l (t = 2.71, p = 0.009), in FPI of
0.8 μU/ml (n.s.) and 2.7 μU/ml (t = 2.74, p = 0.008), in
HOMA Index of 0.8 (n.s.) and 1.2 (t = 2.77, p = 0.008), in
HbA1c of 0.3% (n.s.) and 0.7% (t = 4.90, p<0.001), in TC
of 0.25 mmol/l (n.s.) and 0.31 mmol/l (t = 2.79, p = 0.008),
in LDL-C of 0.13 mmol/l (t = 3.11, p = 0.006) and 0.26
mmol/l (t = 4.09, p = 0.002) and in Apo B of 2 mg/dl (n.s.)
and 6 mg/dl (t = 2.71, p = 0.009), while no change was
noted regarding TG plasma concentration.
Neither the psyllium-treated group nor the guar-treat-
ed group experienced any significant change in plasma
HDL-C, Lp(a) or basal homocysteine.
The step 2 AHA diet determined a stabilisation of the
studied metabolic parameters without any significant dif-
ference in comparison to the baseline.
Effects on blood pressure
Long-term supplementation with psyllium is associated
with a significant decrease of SBP after both 4 months and
6 months of treatment: –3.1 (–3.3) mmHg (t = 4.08, p <
0.001) and –5.2 mmHg (t = 6.51, p < 0.001), respectively.
A significant mean 2.2 mmHg decrease in DBP was
also observed after 6 months of supplementation (t =
6.51, p < 0.001).
Guar supplementation is associated with a speedier
improvement in SBP at 4 months (–5.3 mmHg, t = 6.34,
p < 0.001), but this was not confirmed in the ensuing
study visits. No significant effect has been observed as
regards DBP.
The AHA Step 2 diet did not determine a significant
change in blood pressure in comparison to the baseline.
50 Mediterr J Nutr Metab (2010) 3:47–54
Waist circumference (WC)
Long-term treatment with both tested fibres is associated
with a significant improvement in the studied subjects.
In the psyllium-treated patients the WC decrease was
statistically significant after 4 months of supplementa-
tion (–3.9 cm, t = 2.11, p = 0.037) and continued after 6
months (–4.1 cm, t = 8.94, p < 0.001).
In the guar-treated patients the WC decrease was even
statistically significant after the first 4 months of supple-
mentation (–4.60, t = 2.59, p = 0.011); it progressively
continued and was then maintained till 6 months (–5.2, t
= 2.95, p < 0.004).
Combining these facts, at the end of the study we
observed that 12.5% of patients (6 subjects) in the psyl-
lium group did not comply with the criteria for the diag-
nosis of MS against the 2.1% of patients in the guar
group (1 subject). The prevalence of MS in the control
group was not changed by the AHA Step 2 diet.
No patient withdrew from the study because of serious
adverse events. Three patients in the psyllium group and
four in the guar group experienced transient intercurrent
Mediterr J Nutr Metab (2010) 3:47–54
Table 2 Modification of studied parameters during psyllium husk supplementation
Baseline 2 Months 4 Months 6 Months
Body weight (kg) 80.2 ± 4.1 79.1 ± 3.9a,ba, 78.3 ± 3.6a,ba, 76.9 ± 4.1a,b,c
Waist circumference (cm) 100.4 ± 10.3 96.5 ± 7.6a,ba, 96.4 ± 7.4a,ba, 96.3 ± 7.2a,ba,
Glycated haemoglobin (%) 6.7 ± 0.6 6.3 ± 0.7a,b,c 6.2 ± 0.6a,ba, 6.0 ± 0.6a,ba,
Fasting plasma glucose (mmol/l) 6.1 ± 1.2 5.1 ± 1a,b,c 4.9 ± 0.9a,b,c 4.8 ± 0.8a,b,c
Fasting plasma insulin (μU/ml) 25.2 ± 5.1 22.1 ± 5.4a,ba, 21.2 ± 5.3a,ba, 20.1 ± 5.1a,b,c
HOMA Index 7.4 ± 2.9 5.3 ± 1.8a,b,c 4.9 ± 1.4a,b,c 4.5 ± 1.0a,b,c
Total cholesterol (mmol/l) 4.8 ± 0.6 4.6 ± 0.6a,b,c 4.5 ± 0.5a,ba, 4.5 ± 0.5a,ba,
LDL-cholesterol (mmol/l) 2.9 ± 0.3 2.8 ± 0.3a,ba, 2.8 ± 0.3a,ba, 2.7 ± 0.3a,ba,
HDL-cholesterol (mmol/l) 1.10 ± 0.13 1.11 ± 0.13a,b,c 1.06 ± 0.13a,b,c 1.11 ± 0.1a,b,c
Triacylglycerols (mmol/l) 1.8 ± 0.3 1.7 ± 0.3a,b,c 1.6 ± 0.2a,ba, 1.6 ± 0.2a,ba,
Apolipoprotein A-I (mg/dl) 130 ± 18 126 ± 16a,b,c 128 ± 18a,b,c 131 ± 19a,b,c
Apolipoprotein B (mg/dl) 105 ± 22 100 ± 23a,b,c 97 ± 19a,b,c 94 ± 18a,b,c
Lipoprotein (a) (mg/dl) 17.1 ± 7.7 15.3 ± 5.7a,b,c 14.6 ± 4.8a,b,c 15.4 ± 5.9a,b,c
Homocysteine (μmol/l) 9.8 ± 3.1 10.6 ± 2.6a,b,c 10.1 ± 2.6a,b,c 9.9 ± 2.8a,b,c
Fibrinogen (mg/dl) 379 ± 42 362 ± 40aa,a, 365 ± 39a,b,c 361 ± 38b,c
Systolic blood pressure (mmHg) 131.4 ± 4.2 128.1 ± 3.7a,ba, 127.8 ± 3.7a,ba, 126.2 ± 3.6a,ba,
Diastolic blood pressure (mmHg) 84.6 ± 4.4 83.2 ± 3.3a,b,c 85.4 ± 3.6a,b,c 82.4 ± 3.0a,ba,
ap < 0.01 in comparison to baseline (ANOVA test); bp < 0.01 in comparison to AHA Step 2 diet group (ANCOVA test); cp < 0.01 in comparison
to the guar group (ANCOVA test)
Table 3 Modification of studied parameters during partially hydrolysed guar gum supplementation
Baseline 2 Months 4 Months 6 Months
Body weight (kg) 79.9 ± 4.5 77.5 ± 3.9a,b,c 77.9 ± 4.3a,b 78.3 ± 4.4a,b
Waist circumference (cm) 101.7 ± 9.5 96.4 ± 7.3a,ba, 96.3 ± 7.4a,b 96.5 ± 7.7a,b
Glycated haemoglobin (%) 6.8 ± 0.7 6.5 ± 0.8a,b,c 6.2 ± 0.7a,b 6.1 ± 0.7a,b
Fasting plasma glucose (mmol/l) 6.0 ± 1.3 5.4 ± 0.7a,ba, 5.4 ± 0.7a,b 5.33 ± 0.8a,b
Fasting plasma insulin (μU/ml) 24.9 ± 5.8 24.1 ± 4.0a,b,c 22.5 ± 2.2a,b 22.2 ± 2.8a,ba,
HOMA Index 7.2 ± 2.5 6.4 ± 2.2a,b,c 6.1 ± 1.9a,b 6.0 ± 1.8ba,
Total cholesterol (mmol/l) 4.9 ± 0.6 4.7 ± 0.6a,b,c 4.6 ± 0.7a,b 4.6 ± 0.7ba,
LDL-cholesterol (mmol/l) 3.0 ± 0.4 2.9 ± 0.4a,ba, 2.7 ± 0.4a,b 2.7 ± 0.3a,b
HDL-cholesterol (mmol/l) 1.2 ± 0.1 1.06 ± 0.13a,b,c 1.11 ± 0.1a,b 1.13 ± 0.07a,b
Triacylglycerols (mmol/l) 1.7 ± 0.2 1.6 ± 0.2a,b,c 1.6 ± 0.2a,b 1.6 ± 0.3a,b
Apolipoprotein A-I (mg/dl) 129 ± 16 127 ± 15a,b,c 129 ± 170a,b 127 ± 16a,b
Apolipoprotein B (mg/dl) 107 ± 25 105 ± 21a,b,c 102 ± 24a,b 101 ± 26a,ba,
Lipoprotein (a) (mg/dl) 15.9 ± 6.4 146 ± 59a,b,c 139 ± 49a,b 144 ± 49a,b
Homocysteine (μmol/l) 9.6 ± 2.8 9.0 ± 2.4a,b,c 9.6 ± 3.0a,b 9.1 ± 2.6a,b
Fibrinogen (mg/dl) 384 ± 46 3770 ± 400a,b,c 3710 ± 390a,b 373 ± 400a,b
Systolic blood pressure (mmHg) 131.6 ± 4.0 127.7 ± 4.0aa,a, 129.1 ± 3.9aa, 128.2 ± 3.7aa,
Diastolic blood pressure (mmHg) 85.2 ± 3.6 84.1 ± 3.7a,b,c 83.6 ± 3.6a,b 83.4 ± 3.5a,b
ap < 0.01 in comparison to baseline (ANOVA test); bp < 0.01 in comparison to AHA Step 2 diet group (ANCOVA test); cp < 0.01 in comparison
to the psyllium group (ANCOVA test)
abdominal bloating and one patient in the psyllium group
and three of the guar group withdrew after 3 months of
treatment for this reason. One patient in the psyllium
group and three patients in the guar group also experi-
enced intercurrent diarrhoea, but no one withdrew from
the study for this reason.
Prevention of disease rather than its alleviation or cure
has always been the aim of healthcare professionals.
While this goal has been achieved for many infectious
diseases through improvements in hygiene and vaccina-
tion, as well as acute deficiency diseases such as scurvy,
less progress has been made with chronic diseases like
atherosclerosis-related diseases [27]. The clustering of
several metabolic and cardiovascular disease risk factors
has been termed the MS. The MS seems to result from a
collision between susceptible “thrifty genes” and a soci-
ety characterised by an increased prevalence of obesity
and a sedentary lifestyle [28]. The typical patient is char-
acterised by abdominal obesity, a varying degree of glu-
cose intolerance, dyslipidaemia and/or hypertension. The
components of the MS are associated with insulin resist-
ance, disturbances of coagulation and fibrinolysis,
endothelial dysfunction and elevated markers of sub-clin-
ical inflammation [29].
As suggested by the NCEP ATP III [15], the first ther-
apeutic approach to the MS should be improvement of
lifestyle and diet. Among dietary suggestions, the need to
increase fibre intake with nutrients or supplements is
highlighted [30]. Among supplemented fibres, those that
appear to have the best metabolic effect are the soluble
ones: psyllium, guar, pectin and oats [31]. Dietary fibre
may also be related inversely to blood pressure and
dietary supplementation, which seems to have a slight
blood pressure-lowering effect [32–34].
While oats are a food per se and pectins are widely
available in different fruits, psyllium and guar have to be
taken as dietary supplements. So, we decided to test the
long-term effect of dietary supplementation of psyllium
or guar, the most widely available isolated soluble fibres
on the Italian market, on the clinical features of the MS.
Our results show that a long-term supplementation
with moderately high dosages of soluble fibre is able to
improve most parameters related to the MS. In fact, com-
paring the effects of psyllium and guar supplementation
of patients affected by MS we observed that both kinds of
fibre are able to significantly improve BMI (–2.9% and
–3.3%, respectively), FPG (–16.4% and –9.3%, respec-
tively) and LDL-C (–4.4% and –4.3%, respectively) after
4 months of treatment, and a larger range of metabolic
parameters after 6 months: BMI (–7.2% and –6.5%,
respectively), FPG (–27.9% and –11.1%, respectively),
FPI (–20.4% and –10.8%, respectively), HOMA Index
(–39.2% and –16.7%, respectively), HbA1c (–10.4% and
–10.3%, respectively), TC (–7.5% and –6.3%, respective-
ly), LDL-C (–7.9% and –8.5%, respectively) and Apo B
(–10.5% and –5.6%, respectively). Apart from the speed
and efficacy, only the 6-month psyllium supplementation
exerted a significant improvement on plasma TG concen-
tration (–13.3%) and on SBP (–3.9%) and DBP (–2.6%),
the two main components of the MS. These data are rel-
evant and justify why at the end of the study 12.5% of
patients in the psyllium group did not comply with the
52 Mediterr J Nutr Metab (2010) 3:47–54
Table 4 Modification of studied parameters during AHA Step 2 diet
Baseline 2 Months 4 Months 6 Months
Body weight (kg) 80.1 ± 4.3 79.4 ± 4.2a,b,c 78.7 ± 4.6a,c,c 78.9 ± 4.3a,c
Waist circumference (cm) 102.0 ± 8.3 96.4 ± 6.4a,b,c 96.9 ± 7.1a,b,c 99.5 ± 7.3b,c
Glycated haemoglobin (%) 6.6 ± 0.9 6.5 ± 0.9b,b,c 6.5 ± 0.4b,c,c 6.6 ± 0.7b,c
Fasting plasma glucose (mmol/l) 6.1 ± 1.3 5.5 ± 0.8a,b,c 5.7 ± 0.9b,c,c 5.9 ± 0.8b,c
Fasting plasma insulin (μU/ml) 25.0 ± 5.5 24.3 ± 4.2b,b,c 23.8 ± 2.9b,c,c 24.2 ± 3.8b,c
HOMA Index 7.2 ± 2.8 6.6 ± 2.1b,b,c 6.5 ± 2.4b,c,c 6.6 ± 1.9b,c
Total cholesterol (mmol/l) 4.8 ± 0.7 4.5 ± 0.6a,b,c 4.6 ± 0.9b,c,c 5.0 ± 0.7b,c
LDL-cholesterol (mmol/l) 3.0 ± 0.3 2.9 ± 0.5b,c,c 2.9 ± 0.7b,c,c 2.9 ± 0.5b,c
HDL-cholesterol (mmol/l) 1.1 ± 0.1 1.12 ± 0.11a,b,c 1.11 ± 0.14,c,c,c 1.12 ± 0.15a,b,c
Triacylglycerols (mmol/l) 1.7 ± 0.3 1.5 ± 0.3a,b,c 1.5 ± 0.6a,b,c 1.6 ± 0.4b,c
Apolipoprotein A-I (mg/dl) 129 ± 14 132 ± 16a,b,c 131 ± 17,c,c,c 128 ± 14,c,c
Apolipoprotein B (mg/dl) 106 ± 20 101 ± 19a,b,c 101 ± 23b,c,c 105 ± 22b,c
Lipoprotein (a) (mg/dl) 17 ± 7 17 ± 6a,b,c 18 ± 5a,b,c 16 ± 6a,b,c
Homocysteine (μmol/l) 9.8 ± 2.9 9.4 ± 1.4a,b,c 9.7 ± 2.8a,b,c 9.6 ± 2.9a,b,c
Fibrinogen (mg/dl) 380 ± 48 371 ± 29a,b,c 369 ± 31a,b,c 374 ± 42a,b,c
Systolic blood pressure (mmHg) 131.0 ± 3.7 129.2 ± 4.1b,c,c 129.3 ± 4.2b,c,c 130.0 ± 3.9b,c
Diastolic blood pressure (mmHg) 84.5 ± 3.9 83.9 ± 3.8a,b,c 83.5 ± 3.7a,b,c 83.8 ± 4.0b,c
ap < 0.01 in comparison to baseline (ANOVA test); bp < 0.01 in comparison to the psyllium group (ANCOVA test); cp < 0.01 in comparison to
the guar group (ANCOVA test)
criteria for the diagnosis of the MS compared with only
the 2.1% in the guar group.
No statistically significant association was found
between body weight loss in the whole patient sample or
in the subsamples, probably because of the relatively
small patient sample and the relatively high standard
deviation of body weight change.
Previously randomised clinical trials and meta-analy-
ses demonstrated the efficacy of soluble fibres, and in
particular of psyllium and guar gum, as antihypercholes-
terolaemic agents in moderately hypercholesterolaemic
subjects and as a glycaemic improver in diabetic subjects
[9, 35]. Our studies confirm the previously observed
effect highlighting the possibility that long-term treat-
ment with highly dosed soluble fibres could significantly
improve parameters related to insulin resistance, the
pathogenetic basis of the MS and type 2 diabetes [36].
This effect appears to be much more relevant with psylli-
um supplementation than with guar gum.
Data on the effects of both psyllium and guar gum on
body weight management are promising, but as yet not
sufficient to recommend the current use of soluble fibres
as a therapeutic agent in this field. The main reasons are
the relative brevity of the studies carried out to date and
the relatively low dosage tested [37]: in our study, car-
ried out with high daily dosage of fibres for one year,
both soluble fibres contributed significantly to the body
weight decrease observed in the patients, even though
the dosages differed. This effect could be one of the
main ones responsible for the observed long-term
improvement in metabolic parameters during fibre sup-
Overall, entering the pre- and post-treatment data into
software specifically created to estimate the 5-year risk
for a major cardiovascular event in the Italian population
[38], we observed that the baseline relative risk for each
subject/5 years for 1000 patients treated with psyllium
decreased from 0.78 ± 0.09 to 0.68 ± 0.08, without sig-
nificant differences between the sexes. The relative risk
for patients treated with guar decreased from 0.77 ± 0.08
to 0.67 ± 0.10, without significant differences between
the sexes. Although relatively small in terms of patient
treatment, the observed reduction in cardiovascular dis-
ease risk is likely to be significant on a population basis.
The main limitation of our study is the lack of a dou-
ble-blind design (very hard because of the different
organoleptic characteristics of the two fibres). However,
to the best of our knowledge, this is the first clinical trial
that directly compares the long-term metabolic effect of
a high daily supplementation of soluble fibres for
patients affected by the MS and the trial design was
strengthened by a third control group only treated with a
non-supplemented diet.
Because of the relatively small sample of selected
patients in this study, the results should be extrapolated
cautiously, even though other studies have previously
confirmed the good long-term tolerability of this kind of
treatment [39, 40].
Therefore, the observed results show how fibre sup-
plementation, when recommended, has to be person-
alised on the basis of the specific prevalent metabolic
problem of each patient. In conclusion, our results show
that both fibres could have a positive effect in the man-
agement of the patient affected by multiple cardiometa-
bolic risk factors. However, psyllium could be more
strongly indicated for patients that have to reduce a large
number of cardiovascular risk factors such as hypercho-
lesterolaemia, hypertriglyceridaemia, hyperglycaemia
and hypertension, while guar gum use is associated to a
more rapid body loss effect, which could support patient
compliance to the suggested diet (even though after 4
months the body weight loss associated to either psylli-
um and guar intake become similar).
SBP Systolic blood pressure
DBP Diastolic blood pressure
TC Total cholesterol
LDL-C Low-density lipoprotein cholesterol
HDL-C High-density lipoprotein cholesterol
TG Triglycerides (triacylglycerols)
ApoAI Apolipoprotein AI
ApoB Apolipoprotein B
Lp(a) Lipoprotein (a)
FPG Fasting plasma glucose
FPI Fasting plasma insulin
HOMA Index homeostasis assessment index
HbA1c Glycated haemoglobin
FBG Fibrinogenaemia
Hcys Basal homocysteinaemia
Conflict of interest The authors declare that they have no conflict of
interest related to the publication of this manuscript.
1. Pearson TA, Bazzarre TL, Daniels SR et al (2003) American
Heart Association guide for improving cardiovascular health at
the community level. Circulation 107:645–651
2. WHO (2003) Population nutrient intake goals for preventing diet-
related chronic diseases. In: Diet, nutrition and the prevention of
chronic diseases. WHO Technical report Series 916:46–83
3. Eastwood MA, Passmore R (1983) Dietary fibre. Lancet
4. Truswell AS (1995) Dietary fibre and plasma lipids. Eur J Clin
Nutr 49[Suppl]:S105–S109
5. Glore SR, Van Treeck D, Knehans AW, Guild M (1994) Soluble
fiber and serum lipids: a literature review. J Am Diet Assoc
6. Kris-Etherton PM, Krummel D, Russell ME et al (1988) The
effect of diet on plasma lipids, lipoproteins, and coronary heart
disease. J Am Diet Assoc 88:1373–1400
Mediterr J Nutr Metab (2010) 3:47–54
7. Brown L, Rosner B, Willett WW, Sacks FM (1999) Cholesterol-
lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr
8. Burke V, Hodgson JM, Beilin LJ et al (2001) Dietary protein and
soluble fiber reduce ambulatory blood pressure in treated hyper-
tensives. Hypertension 38:821–826
9. Sierra M, Garcia JJ, Fernandez N et al (2002) Therapeutic effects
of psyllium in type 2 diabetic patients. Eur J Clin Nutr
10. Anderson JW, Allgood LD, Turner J et al (1999) Effects of
psyllium on glucose and serum lipid responses in men with type
2 diabetes and hypercholesterolemia. Am J Clin Nutr
11. Delargy HJ, O’Sullivan KR, Fletcher RJ, Blundell JE (1997)
Effects of amount and type of dietary fibre (soluble and insoluble)
on short-term control of appetite. Int J Food Sci Nutr 48:67–77
12. Turnbull WH, Thomas HG (1995) The effect of a Plantago ovata
seed containing preparation on appetite variables, nutrient and
energy intake. Int J Obes Relat Metab Disord 19:338–342
13. Landin K, Holm G, Tengborn L, Smith U (1992) Guar gum
improves insulin sensitivity, blood lipids, blood pressure, and
fibrinolysis in healthy men. Am J Clin Nutr 56:1061–1065
14. van Nieuwenhoven MA, Kovacs EM, Brummer RJ et al (2001)
The effect of different dosages of guar gum on gastric emptying
and small intestinal transit of a consumed semisolid meal. J Am
Coll Nutr 20:87–91
15. NCEP expert panel (2001) Expert Panel on detection, evaluation
and treatment of high blood cholesterol in adults. Executive sum-
mary of the third report of the National Cholesterol Education
Program (NCEP) (Adult Treatment Panel III). JAMA
16. Kraus RM, Eckel RH, Howerd B et al (2000) AHA Dietary
Guidelines: revision 2000. A statement for healthcare professio-
nals from the Nutrition Committee of the American Heart
Association. Circulation 102:2284–2299
17. Gaddi A, Cicero AFG, Dormi A et al (2001) The realisation of a
project aimed at reducing the plasmatic lipid level in a large
Italian rural population improves the mean calcium daily intake:
the Brisighella Study. Eur J Clin Nutr 55:97–106
18. Warnick GR, Benderson J, Albers JJ (1982) Dextran sulfa-
te–Mg2+ precipitation procedure for quantitation of high-density-
lipoprotein cholesterol. Clin Chem 28:1379–1388
19. De Loof H, Rosseneu M, Yang CY et al (1987) Human apolipo-
protein B: analysis of internal repeats and homology with other
apolipoproteins. J Lipid Res 28:1455–1465
20. Uterman G, Weber W (1987) Protein composition of lipoprotein
(a). J Clin Invest 80:458–465
21. European Diabetes Policy Group (1999) A desktop guide to type
2 diabetes mellitus. Diab Med 16:716–730
22. Heding LG (1972) Determination of total serum insulin (IRI) in
insulin-treated diabetic patients. Diabetologia 8:260–266
23. Bunn HF, Gabbay HK, Gallop PM (1978) The glycosylation of
haemoglobin. Relevance to diabetes mellitus. Science 200:21–27
24. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis
model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man.
Diabetologia 28:412–419
25. Araki A, Sako Y (1987) Determination of free and total homocy-
steine in human plasma by high performance chromatography
with fluorescence detection. J Chromatography 422:43–52
26. Norman GR, Streiner DL (2000) Biostatistics. The bare essen-
tials, 2nd edn. B.C. Decker, Hamilton, Canada, pp 139–144
27. Marks V (2003) The metabolic syndrome. Nurs Stand 17:37–44
28. Wilson PW, Grundy SM (2003) The metabolic syndrome: a prac-
tical guide to origins and treatment: Part II. Circulation
29. Deedwania PC (2003) Mechanisms of endothelial dysfunction in
the metabolic syndrome. Curr Diab Rep 3:289–292
30. Carson JA (2003) Nutrition therapy for dyslipidemia. Curr Diab
Rep 3:397–403
31. Brown L, Rosner B, Willett WW, Sacks FM (1999) Cholesterol-
lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr
32. Appel LJ, Moore TJ, Obarzanek E et al (1997) A clinical trial of
the effects of dietary patterns on blood pressure. DASH
Collaborative Research Group. N Engl J Med 336:1117–1124
33. Ascherio A, Rimm EB, Giovanucci EL et al (1992) A prospecti-
ve study of nutritional factors and hypertension among US men.
Circulation 86:1475–1484
34. Stamler J, Caggiula AW, Grandits GA (1997) Relation of body
mass and alcohol, nutrient, fiber, and caffeine intakes to blood
pressure in the special intervention and usual care groups in the
Multiple Risk Factor Intervention Trial. Am J Clin Nutr
35. Slavin JL, Greenberg NA (2003) Partially hydrolyzed guar gum:
clinical nutrition uses. Nutrition 19:549–552
36. Grundy SM, Hansen B, Smith SC Jr et al for Conference
Participants (2004) Clinical Management of Metabolic Syndro -
me. Report of the American Heart Association/National Heart,
Lung, and Blood Institute/American Diabetes Association
Conference on Scientific Issues Related to Management.
Circulation 109:551–556
37. Pittler MH, Ernst E (2004) Dietary supplements for body-weight
reduction: a systematic review. Am J Clin Nutr 79:529–536
38. Menotti A, Lanti MP, Puddu PE (2000) Twenty-five-year cardiova-
scular disease incidence among middle-aged men. Disease burden,
time shape, predictors, risk probabilities. Ital Heart J 1:749–757
39. Oliver SD (2000) The long-term safety and tolerability of ispa-
ghula husk. J R Soc Health 120:107–111
40. Knopp RH, Superko HR, Davidson M et al (1999) Long-term
blood cholesterol-lowering effects of a dietary fiber supplement.
Am J Prev Med 17:18–23
54 Mediterr J Nutr Metab (2010) 3:47–54
... Increased total cholesterol (TC) and lowdensity lipoprotein cholesterol (LDL-C) are widespread cardiovascular risk factors [2][3][4], sharply favoring the progression of coronary heart disease [5,6]. Soluble dietary fibers have hypolipidemic effects and thus may be a tool in the management of hypercholesterolemia; this fiber category includes, pectins, psyllium, beta-glucans, and gums [7]. Regarding gums, several studies have proven overall effects in the amelioration of all traditional lipid indices, beyond miscellaneous complications (type 2 diabetes mellitus, hypertension, obesity, constipation, diarrhea, and irritable bowel syndrome [7][8][9][10]. ...
... Soluble dietary fibers have hypolipidemic effects and thus may be a tool in the management of hypercholesterolemia; this fiber category includes, pectins, psyllium, beta-glucans, and gums [7]. Regarding gums, several studies have proven overall effects in the amelioration of all traditional lipid indices, beyond miscellaneous complications (type 2 diabetes mellitus, hypertension, obesity, constipation, diarrhea, and irritable bowel syndrome [7][8][9][10]. ...
... Of these articles, 26 studies were excluded due to the following reasons: cosupplementation with other components (n=2), irrelevant articles (n=10), no control group (n=6), study design (n=2), and insufficient data reported for outcomes (n=3). Twenty-five eligible articles [7,17,18,22,23,[29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] with 23 arms on TC, 18 arms on LDL-C, 23 on HDL-C, and 25 on TG were included in the final quantitative analysis (Figure 1). ...
Background and aims Guar gum can be used as an adjuvant in the treatment of dyslipidemia. However, based on data from different studies, the effectiveness of this product is not uniform. Therefore, we conducted a dose-response meta-analysis between guar gum supplementation and lipid profile. Methods and Results Five databases (Scopus, Web of Science, PubMed/Medline, Embase, and Google Scholar) were searched to identify relevant articles published up to July 2020. The weighted mean difference (WMD) was derived based on the random-effects model. Overall findings were generated from 25 eligible trials. Patients’ conditions included hyperlipidemia, diabetes, metabolic syndrome, hypertension, overweight, carotid endarterectomy, and menopausal women. Prescribed gum dose varied between 100 mg/d and 30 g/d for 1 to 24 months. Compared with control groups, guar gum supplementation decreased total cholesterol (TC) by -20.41 mg/dL (95% CI: -26.76 to -14.07; P<0.001) and low-density lipoprotein-cholesterol (LDL-C) by -17.37 mg/dL (95% CI: -23.60 to -11.13; P<0.001), but did not change triglycerides (TG) (WMD: -6.53 mg/dL, 95% CI: -16.03 to 2.97; P=0.178) and high-density lipoprotein-cholesterol (HDL-C) (WMD: -0.62 mg/dL, 95% CI: -1.68 to 0.44, P=0.252). Conclusions Guar gum supplementation significantly reduced serum LDL-C and TC levels in patients with cardiometabolic problems, but had neutral effects on TG and HDL-C levels.
... Three additional reports were included after searching the 1130 records that cited the included studies and the 823 references of the included studies using Web of Science. The study by Cicero et al. [51] was not available on Web of Science and we used Google Scholar for citation searching. In total, we included 26 reports covering 22 studies and 27 cohorts. ...
... None of the eligible studies examined stool calprotectin levels. (1)/(2) indicate cohort 1 and 2 of study [51][52][53]55,56,[62][63][64][65][67][68][69][70][71][72][74][75][76]. (1)/(2) indicate cohort 1 and 2 of study [51,52,[54][55][56][61][62][63][64][65][70][71][72]75,76]. ...
... (1)/(2) indicate cohort 1 and 2 of study [51][52][53]55,56,[62][63][64][65][67][68][69][70][71][72][74][75][76]. (1)/(2) indicate cohort 1 and 2 of study [51,52,[54][55][56][61][62][63][64][65][70][71][72]75,76]. ...
Full-text available
The prevalence of overweight and obesity is rising rapidly, currently affecting 1.9 billion adults worldwide. Prebiotic dietary fibre supplementation is a promising approach to improve weight loss and reduce metabolic complications in overweight and obese subjects due to modifications of the microbiota composition and function. Previous systematic reviews and meta-analyses addressing similar questions revealed discordant evidence and/or are outdated. We searched MEDLINE, Embase, Google Scholar, and forward and backward citations for randomised controlled trials (RCTs) with isolated soluble dietary fibre supplementation for at least 12 weeks in overweight and obese patients measuring body weight, published through April 2022. We expressed the results as mean differences (MDs) using the random-effects model of the metafor package in R and assessed risk of bias using the Cochrane RoB2 tool. We conducted the study according to the PRISMA guidelines and registered the protocol on PROSPERO (CRD42022295246). The participants with dietary fibre supplementation showed a significantly higher reduction in body weight (MD −1.25 kg, 95% CI −2.24, −0.25; 27 RCTs; 1428 participants) accompanied by a significant decrease in BMI, waist circumference, fasting blood insulin, and HOMA-IR compared to the control group. Certainty of evidence was high, paving the way for the implementation of isolated soluble dietary fibre supplementation into clinical practice.
... Fasting glucose, insulin, and lipid panels were not significantly altered after the prebiotic supplementation compared to the placebo. Several studies show clinically meaningful decreases in fasting or postprandial blood glucose and insulin concentrations in response to fiber supplementation (1,127,128). However, many of these studies were conducted in participants with elevated baseline values of these cardiometabolic parameters, such as individuals with metabolic syndrome (127) or type 2 diabetes (129), or in healthy participants (130,131) but at much higher fiber doses (e.g., 38 vs. 12 g/d in this study) (1). ...
... Several studies show clinically meaningful decreases in fasting or postprandial blood glucose and insulin concentrations in response to fiber supplementation (1,127,128). However, many of these studies were conducted in participants with elevated baseline values of these cardiometabolic parameters, such as individuals with metabolic syndrome (127) or type 2 diabetes (129), or in healthy participants (130,131) but at much higher fiber doses (e.g., 38 vs. 12 g/d in this study) (1). Other studies show results that are in line with this study demonstrating no significant differences in cardiometabolic profiles between groups supplemented with fiber diet vs. control diet (132,133). ...
Full-text available
Dietary fiber, a nutrient derived mainly from whole grains, vegetables, fruits, and legumes, is known to confer a number of health benefits, yet most Americans consume less than half of the daily recommended amount. Convenience and affordability are key factors determining the ability of individuals to incorporate fiber-rich foods into their diet, and many Americans struggle to access, afford, and prepare foods rich in fiber. The objective of this clinical study was to test the changes in microbial community composition, human metabolomics, and general health markers of a convenient, easy to use prebiotic supplement in generally healthy young participants consuming a diet low in fiber. Twenty healthy adults participated in this randomized, placebo-controlled, double-blind, crossover study which was registered at as NCT03785860. During the study participants consumed 12 g of a prebiotic fiber supplement and 12 g of placebo daily as a powder mixed with water as part of their habitual diet in randomized order for 4 weeks, with a 4-week washout between treatment arms. Fecal microbial DNA was extracted and sequenced by shallow shotgun sequencing on an Illumina NovaSeq. Plasma metabolites were detected using liquid chromatography–mass spectrometry with untargeted analysis. The phylum Actinobacteria, genus Bifidobacterium , and several Bifidobacterium species ( B. bifidum, B. adolescentis, B. breve, B. catenulatum , and B. longum) significantly increased after prebiotic supplementation when compared to the placebo. The abundance of genes associated with the utilization of the prebiotic fiber ingredients ( sacA, xfp, xpk ) and the production of acetate ( poxB, ackA ) significantly changed with prebiotic supplementation. Additionally, the abundance of genes associated with the prebiotic utilization ( xfp, xpk ), acetate production ( ackA ), and choline to betaine oxidation ( gbsB ) were significantly correlated with changes in the abundance of the genus Bifidobacterium in the prebiotic group. Plasma concentrations of the bacterially produced metabolite indolepropionate significantly increased. The results of this study demonstrate that an easy to consume, low dose (12 g) of a prebiotic powder taken daily increases the abundance of beneficial bifidobacteria and the production of health-promoting bacteria-derived metabolites in healthy individuals with a habitual low-fiber diet. Clinical Trial Registration , identifier: NCT03785860
... Based on the multiple benefits of the soluble polysaccharides (fibers) in humans [20,21], the products derived from seeds and seed chaff from plantain are placed in the category of food-medicines [22][23][24][25][26]. Thus, they are currently used as active ingredients for special diets, and dietary and food supplements too, being attributed to a plethora of digestive benefits: e.g., constipation and diarrhea benefits, healing gastric and intestinal mucosa damages, managing inflammatory bowel diseases, food intolerance, and disbiosis. Extended digestive benefits of seed and chaff plantain-derived products are also explained by mucilages ability of extracting water from medium, therefore they collect water, toxins, bacteria, and many other compounds in the feces, explaining all, constipation and diarrhea benefits and usefulness, detoxifying activity [23][24][25][26], cholesterol, glucose, fatty acids and bile caption activity as well [27][28][29][30]. ...
Full-text available
In this study, six laser radiation (488 nm/40 mW, 514 nm/15 mW, 532 nm/20 mW, 552 nm/15 mW, 660 nm/ 75 mW, and at 785 nm/70 mW) were tested on the aqueous extracts of leaves of Plantago lanceolata L. to compare extraction efficacy and antioxidant and cell viability effects in vitro. Briefly, in comparison with the control extract, laser extracts at 488, 514, 532, and 552 nm revealed small acquisitions of total extractible compounds in samples (up to 6.52%; laser extracts at 488 and 532 nm also revealed minerals and micro-elements increases (up to 6.49%); the most prominent results were obtained upon Fe (up to 38%, 488 nm), Cr (up to 307%, 660 nm), and Zn (up to 465%, 532 nm). Laser extracts at 488, 514, 552, and 785 nm proved more intense antioxidant capacity than the control sample, while laser extract at 660 nm indicated clear pro-oxidant effects. Caco-2 cells study indicated stimulatory activity for the extracts at 488 nm, no effects at 532 nm, and the decrease of the cell viability in the case of extracts at 660 nm respectively. Further studies are necessary to understand the pro-oxidant effects observed in the case of extracts exposed to laser radiation at 660 nm.
Dysglycemia is a disease state preceding the onset of diabetes and includes impaired fasting glycemia and impaired glucose tolerance. This review aimed to collect and analyze the literature reporting the results of clinical trials evaluating the effects of selected nutraceuticals on glycemia in humans. The results of the analyzed trials, generally, showed the positive effects of the nutraceuticals studied alone or in association with other supplements on fasting plasma glucose and post‐prandial plasma glucose as primary outcomes, and their efficacy in improving insulin resistance as a secondary outcome. Some evidences, obtained from clinical trials, suggest a role for some nutraceuticals, and in particular Berberis, Banaba, Curcumin, and Guar gum, in the management of prediabetes and diabetes. However, contradictory results were found on the hypoglycemic effects of Morus, Ilex paraguariensis, Omega‐3, Allium cepa, and Trigonella faenum graecum, whereby rigorous long‐term clinical trials are needed to confirm these data. More studies are also needed for Eugenia jambolana, as well as for Ascophyllum nodosum and Fucus vesiculosus which glucose‐lowering effects were observed when administered in combination, but not alone. Further trials are also needed for quercetin.
Full-text available
Insulin resistance is a metabolic disorder that is increasing worldwide and is associated with some of the most common diseases affecting modern societies including diabetes, hypertension, obesity, and coronary heart disease. Changes in diet and physical activity have a profound effect on lowering the risk and cost of managing insulin resistance compared to the pharmacological approach. An interventional study of 16 weeks explored the effect of Psyllium husk fiber in combination with lifestyle modification on insulin resistance among the centrally obese school teachers of district Malakand Khyber Pakhtunkhwa. One Hundred twenty school teachers with central obesity, aged 40-60 years, with no chronic disease history were divided into four subgroups (n = 30) with equal gender bifurcation; a control group, lifestyle modification (LSM) group, psyllium husk fiber (PSH) group, and the combined intervention of LSM & PSH group. Fasting serum was collected to analyze fasting blood glucose, and insulin resistance by using the HOMA-IR method at baseline and post-intervention. A significant effect of the intervention was observed on fasting blood glucose. The combined group of LSM&PSH showed the highest mean change of −7.5 ± 2.6 mg/dl (−9%), followed by the PSH group with a mean change of −6.3 ± 2.1 mg/dl, (−7%). Likewise a significant effect ( P
Some types of dietary fibers show beneficial effects in randomized controlled clinical studies. In the small bowel, beneficial effects include cholesterol lowering and improved glycemic control. Only gel-forming fibers (e.g., psyllium) are clinically proven to provide both of these health benefits, and the beneficial effects are highly correlated with the viscosity of the gelling fiber. In the large bowel, only fibers that resist fermentation and remain intact throughout the large bowel can be present in stool and can provide a laxative effect. Fiber supplements may appear to be a convenient and concentrated source of fiber, but most isolated fibers have no clinical evidence of a health benefit. Fiber recommendations should be based on reproducible clinical evidence of a meaningful health benefit.
Objective Dietary supplements and alternative therapies are commercialized as a panacea for obesity/weight gain as a result of the minimal regulatory requirements in demonstrating efficacy. These products may indirectly undermine the value of guideline-driven obesity treatments. Included in this study is a systematic review of the literature of purported dietary supplements and alternative therapies for weight loss. Methods A systematic review was conducted to evaluate the efficacy of dietary supplements and alternative therapies for weight loss in participants aged ≥18 years. Searches of Medline (PubMed), Cochrane Library, Web of Science, CINAHL, and Embase (Ovid) were conducted. Risk of bias and results were summarized qualitatively. Results Of the 20,504 citations retrieved in the database search, 1,743 full-text articles were reviewed, 315 of which were randomized controlled trials evaluating the efficacy of 14 purported dietary supplements, therapies, or a combination thereof. Risk of bias and sufficiency of data varied widely. Few studies (n = 52 [16.5%]) were classified as low risk and sufficient to support efficacy. Of these, only 16 (31%) noted significant pre/post intergroup differences in weight (range: 0.3-4.93 kg). Conclusions Dietary supplements and alternative therapies for weight loss have a limited high-quality evidence base of efficacy. Practitioners and patients should be aware of the scientific evidence of claims before recommending use.
Guar gum has been used in the management of hypercholesterolemia, constipation, weight loss, type 2 diabetes mellitus and hypertension. Our aim was to verify the hypothesis that Guar gum can be used as an alternative to pharmacological agents in the treatment of mild hypertension. Thus, we conducted a systematic review and meta-analysis to evaluate the effectiveness of Guar gum in reducing blood pressure. We searched the Cochrane Library, PubMed/Medline, Scopus and Google Scholar databases for studies published in the English language up to June 2020 which evaluated the effects of gum consumption on systolic blood pressure (SBP) and diastolic blood pressure (DBP). Nine randomized clinical trials with suitable comparison groups (placebo/control) reported SBP and DBP as outcome measures. These trials involved in total 640 participants. The overall results indicated that the consumption of gum resulted in a significant change in SBP (WMD: −1.190 mmHg, 95% CI: −2.011, −0.370) and DBP (WMD: −1.101 mmHg, 95% CI: −1.597, −0.605). Moreover, the greatest reduction in blood pressure was seen in patients with type 2 diabetes mellitus and metabolic syndrome who consumed Guar gum (WMD: −3.375 mmHg). In addition, there was a significant decrease in SBP if the gum dosage was > 15 g (WMD: −6.637 mmHg) and if the intervention duration was > 12 weeks (WMD: −1.668 mmHg). The results of the present dose-response meta-analysis support the employment of gum consumption in the reduction of SBP and DBP. Based on the sub-group analyses, we highlight that the greatest decrease in SBP was experienced if the gum dosage was > 15 g and when the intervention lasted > 12 weeks.
This Guide for Improving Cardiovascular Health at the Community Level (Community Guide) is intended to provide persons and organizations interested in improving the cardiovascular health of their communities with a comprehensive list of goals, strategies, and recommendations that might be implemented on a community-wide basis. It targets not only health professionals but also public health practitioners, voluntary health agencies, and community leaders in general. The Community Guide will complement the American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke,1 the American Stroke Association Scientific Statement on the Primary Prevention of Ischemic Stroke,2 AHA/American College of Cardiology (ACC) Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease,3 and the Guidelines for Preventing Ischemic Stroke in Patients with Prior Stroke and Transient Ischemic Attack.4 This Guide differs from these four clinical guidelines because it provides a comprehensive approach to reducing the burden of cardiovascular disease (CVD) through improving the local policies and environment as a means to promote cardiovascular health. Changes toward a healthier environment could be expected to enhance the clinically oriented guidelines because both the primary and secondary prevention guidelines recommend that healthcare providers encourage behavior change in individual patients. Improvements in facilities and resources in the places where people work and live should enhance the achievement of many goals, including: cessation of tobacco use and avoidance of environmental tobacco smoke; reduction in dietary saturated fat, cholesterol, sodium, and calories; increased plant-based food intake; increased physical activity; access to preventive healthcare services; and early recognition of symptoms of heart attack and stroke. Healthcare providers and their patients have better opportunities for successfully implementing the clinical guidelines when they live in such communities. Although complementary to and supportive of the clinical guidelines, the Community Guide provides a fundamentally different …